全球數位治療市場的成長機會

Growth Opportunities in the Global Digital Therapeutics Market

出版日期: 2023年09月21日 | 出版商:

Frost & Sullivan | 英文 97 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預防性醫療保健和市場進入策略刺激新的成長機會

該研究報告提供了全球數位治療 (DTx) 市場的整體和細分收益預測，並強調了全球 DTx 市場參與企業的關鍵成長機會。

患有長期慢性病的患者擴大尋求安全、循證的數位治療，以減少藥物劑量、引發不利事件並限制醫療保健的利用。部分原因是與這些疾病相關的高昂醫療費用以及對有效且負擔得起的解決方案的需求。付款人和醫療保健提供者正在尋求具有成本效益的替代，以提高患者的參與度、依從性和便利性，同時促進基於價值的護理。疾病逆轉和預防性醫療保健解決方案的需求也很高。生命科學 (LS) 公司的目標是開發「圍繞錠劑」的組合藥物，以改善患者的治療體驗。我們也正在尋找對未來藥物研發有用的數位生物標記。 LS 與 DTx 公司合作，擴大其產品線並開發新的治療方法，以滿足未滿足的醫療需求。此外，LS 還幫助 DTx 公司擴大其全球患者覆蓋範圍並實現其健康公平目標。 DTx 供應商和醫療設備公司之間的合作也促進了個體化治療的給藥最佳化。

大多數位醫療技術長期以來無法透過同行評審的報告系統地證明其解決方案的臨床有效性。因此，他們無法獲得法規的「處方箋級」數位治療計劃的獨特特徵，從而同時確保改善患者的治療效果和全面的報銷。在嚴格、高品質、去中心化的臨床試驗的支持下，更多的DTx公司正在利用強大的臨床資料、RWE資料和HEOR來證明產品的安全性和有效性，並推動廣泛的商業化，重點可能會放在資料創建上。

此外，生物製藥、醫療設備和醫療技術的整合將在向整合患者管理和整個患者旅程的整體支持的轉變中發揮關鍵作用。專注於患者體驗的 DTx 公司利用針對不同客戶類型量身定做的各種商業模式，醫生推薦產品，患者在規定的時間內持續使用該產品，看護者24/7 全天候使用該產品。系統必須監控結果並啟用可擴展的解決方案，允許付款人償還使用成本。

DTx 和 LS 公司之間的合作擴大了患者覆蓋範圍，並與風險分擔協議一起提高了擴充性。 DTx療法目前被認為是傳統藥物療法的有效輔助性治療，並受到全面法規。 FDA、NHS 和 CE 等國家和州級法規機構根據特定患者群體臨床結果改善的證據授予處方資格。

美國是全球成長的關鍵市場，其次是歐洲，德國在該地區處於領先地位，因為它對 DTx 採用最具吸引力。這是由於高報銷率以及付款人、醫療保健提供者以及生命科學和醫療設備業的公司的早期採用。

疾病管理應用預計將佔全球 DTx 市場收益的大部分。這些解決方案提高了患者對慢性病管理的參與度，減少了醫療保健利用率，並鼓勵症狀自我管理。因此，醫療保健提供者擴大將這些解決方案涵蓋其輔助治療方法的一部分。糖尿病在治療領域中擁有最高的銷售佔有率，預期年複合成長率較高。這是因為世界上不斷成長的糖尿病人口正在增加對糖尿病管理解決方案的需求。此外，製藥公司與用於互聯護理的數位胰島素管理解決方案之間的合作也在不斷增加。由於全球對心理健康和認知健康解決方案的高需求，以及雇主與 DTx 供應商合作提供提高員工生產力和健康的解決方案，健康和行為管理領域正在不斷成長。收益預計將成長。沉浸式療法正在成為一種針對難以達到的高風險行為健康狀況的有效治療方法，並且可能會增加患者的參與度。

付款人是為 DTx 市場貢獻收益的關鍵商業用戶。預計付款人將透過各種基於價值的付款計劃償還市場收益的 60% 至 66%，患者可根據醫生或處方者的推薦自動獲得這些付款計劃的資格或註冊。此外，醫療保健提供者的角色將至關重要，因為 DTx 解決方案可增強整體處方者體驗並提高當前的護理標準。

人均醫療保健支出分析
DTx 的核准和跨治療領域的多元化
主要市場趨勢
利用 DCT 模型開拓商業性潛力
美國和歐洲的法規預測
DTx-法規展望：亞太地區
法規預測：中東、非洲和加勒比海地區
全球贖回和市場進入趨勢
資金籌措形勢
商業模式描述
Top 5 商業模式總結分析
預測假設和限制
收益和預測
按應用分類的收益預測
收益預測分析
地區收益預測
區域收益預測分析 - 北美和歐洲
區域收益預測分析 - 亞太地區
按地區分類的收益預測分析 - 中東和非洲、拉丁美洲、加勒比海地區
按治療領域分類的收益和預測
收益預測與考察- 治療領域
按業務分類的銷售佔有率
按業務分類的銷售佔有率分析
價格趨勢和預測分析
競爭環境
收益佔有率
收益佔有率分析
主要競爭對手和提供的產品

成長機會分析疾病管理

成長指標
收益和預測
預測分析 - 疾病管理
使用案例- 疾病管理中的採用

成長機會分析行為與健康管理

成長指標
收益和預測
預測分析 - 健康與行為管理
使用案例- 健康與行為管理的採用

成長機會宇宙

成長機會1：以DTx治療癌症相關疼痛，提供疾病預測，提升生活品質
成長機會2：慢性病用藥依從性與個體化輔導解決方案
成長機會 3：預測和預防醫學的數位生物標記
成長機會 4：個體化照護的身臨其境型療法

下一步

下一步
為什麼現在要霜凍？
附件清單
免責聲明

簡介目錄

Product Code: PF19-52

Preventive Care and Market Access Strategies Spur New Growth Opportunities

This study presents Frost & Sullivan's overall market and segment-wise revenue forecasts of the global digital therapeutics (DTx) market and highlights key growth opportunities for global DTx market participants.

Patients with long-term chronic conditions increasingly seek safe, evidence-based digital treatments to reduce their medication dosages, reverse triggers of adverse events, and limit healthcare utilization. This is due to the high cost of care associated with these conditions and the need for effective and affordable solutions. Payers and providers seek cost-effective medication alternatives to improve patient engagement, adherence, and convenience while promoting value-based care. The need for disease-reversal and preventive care solutions is also seeing huge demand. Life sciences (LS) companies aim to develop 'around the pill' combination products to enhance patients' treatment experiences. They are also searching for digital biomarkers to assist in drug discovery in the future. LS is partnering with DTx companies to expand their pipelines and develop new treatments for unmet medical needs. In addition, LS is helping DTx companies grow their patient reach globally and achieve their health equity objectives. Collaborations between DTx vendors and medical device companies are also facilitating dosage optimization for personalized therapeutics.

Most digital health technologies have long suffered from being unable to systematically prove their solutions' clinical efficacy via peer-reviewed reports. Thus, they have never secured the unique distinction of being a regulated and "prescription-grade" digital treatment plan that guarantees improved patient outcomes and comprehensive reimbursement at the same time. With the support of rigorous and high-quality decentralized clinical trials, more DTx companies will focus on generating strong clinical, RWE, and HEOR data to prove the safety and effectiveness of their products and drive widespread commercialization.

Additionally, the convergence of biopharma, medical devices, and health technology will play a significant role in shifting toward integrated patient management and holistically supporting the entire patient journey. DTx companies focused on the patient experience must utilize a variety of business models tailored to different customer types, allowing for scalable solutions that enable physicians to recommend their products, patients to use them consistently for a defined period, caregivers to monitor outcomes round the clock, and payers to reimburse the cost of usage.

Collaboration between DTx and LS companies will increase, enabling broader patient reach and increasing scalability alongside risk-sharing agreements. DTx solutions are now considered valid alternatives or adjuncts to traditional pharmacotherapy and are subject to comprehensive regulation. They have been granted prescription status by national or state-level regulatory agencies, such as the FDA, NHS, and CE, based on evidence of improved clinical outcomes for specific patient groups.

The United States is a significant market for growth on a global scale, followed by Europe, where Germany leads the way owing to the highest DTx adoption attractiveness in this region. It is due to higher reimbursement rates and early adoption by payers, providers, and companies in the life sciences and medical device industries.

The disease management application is expected to make up a significant portion of the DTx market revenue worldwide. These solutions enable better patient engagement in chronic care management, lowering healthcare utilization and encouraging self-management of symptoms. This, in turn, incentivizes providers to incorporate these solutions as part of adjunct treatment approaches. Diabetes is expected to have the highest share in revenue within therapy areas and a high CAGR growth rate. This is due to the increasing demand for diabetes management solutions caused by the rising diabetic population worldwide. Additionally, there has been an increase in partnerships between pharma and digital insulin management solutions for connected care. The wellness and behavior management sector will experience revenue growth due to the high demand for mental and cognitive health solutions globally, as well as employers partnering with DTx vendors to provide solutions that enhance employee productivity and wellness. Immersive therapeutics will emerge as an effective treatment approach targeting hard-to-reach and high-risk behavioral health conditions, enhancing patient engagement.

Payers are the primary business users contributing to DTx market revenue. They are expected to reimburse 60% to 66% of the market revenue through different value-based payment plans that patients will be automatically eligible for or subscribed to based on referrals from physicians or formulary decision-makers. Additionally, the role of the providers will become significant as DTx solutions enhance the entire prescriber experience and elevate the current standard of care.

Strategic Imperatives

Why is it Increasingly Difficult to Grow?
The Strategic Imperative 8™
The Impact of the Top 3 Strategic Imperatives on the Digital Therapeutics Industry
Growth Opportunities Fuel the Growth Pipeline Engine™

Growth Opportunity Analysis

Scope of Analysis
Introduction to DTx Solutions
The Ten Core Principles All DTx Must Follow
DTx Product Categorization
DTx Mechanisms and Delivery Routes
Application, Therapy Area, and Business Segmentation
Market Segmentation By Application
Market Segmentation By Therapy Area
Segmentation by Geography
Key Competitors
Growth Metrics
Growth Drivers
Growth Restraints

Growth Environment

Per Capital Healthcare Spending Analysis
DTx Approval and Diversification Across Therapy Areas
Key Market Trends
Unlocking Commercial Viability Through DCT Model
Regulatory Outlook-United States and Europe
DTx-Regulatory Outlook: APAC
Regulatory Outlook, MENASA, LATAM, and the Caribbean
Global Reimbursement and Market Access Trends
Funding Landscape
Business Model Description
Summary Analysis of the Top 5 Business Models
Forecast Assumptions and Limitations
Revenue Forecast
Revenue Forecast by Application
Revenue Forecast Analysis
Revenue Forecast by Region
Revenue Forecast Analysis by Region-North America and Europe
Revenue Forecast Analysis by Region-APAC
Revenue Forecast Analysis by Region-MENASA, LATAM, and the Caribbean
Revenue Forecast by Therapy Area
Revenue Forecast Discussion-Therapy areas
Revenue Share by Business
Revenue Share Analysis by Business
Pricing Trends and Forecast Analysis
Competitive Environment
Revenue Share
Revenue Share Analysis
Key Competitors and Product Offerings

Growth Opportunity Analysis: Disease Management

Growth Metrics
Revenue Forecast
Forecast Analysis-Disease management
Use Cases-Adoption in Disease Management

Growth Opportunity Analysis: Behavior and Wellness Management

Growth Metrics
Revenue Forecast
Forecast Analysis-Wellness and Behavior Management
Use Cases-Adoption in Wellness and Behavioral Management

Growth Opportunity Universe

Growth Opportunity 1: DTx to Treat Cancer-related Distress, Provide Incidence Prediction, and Elevate QoL
Growth Opportunity 2: Drug Adherence and Personalized Coaching Solutions for Chronic Diseases
Growth Opportunity 3: Digital Biomarkers for Predictive and Preventive Care
Growth Opportunity 4: Immersive Therapeutics for Personalized Care